| |
 |
| 8th annual market access Summit | detailed conference agenda |
 |
| 8:15 am |
Registration & Sponsor Exhibits Open – Continental Breakfast |
| 9:00 am |
Opening Address From Day One Chair
 Tania MacLeod,
President, Pharmaceutical Health Policy & Market Access Strategy, Market Access Solutions; Past-President, Canadian Association for Healthcare Reimbursement |
| 9:15 am |
Key note adress : PMPRB Update
Review of the Patented Medicine Prices Review Board’s Excessive Pricing Guidelines – and how they will affect the industry
In June 2009, the Board released its revised Excessive Pricing Guidelines with an implementation date of January 1, 2010, following extensive consultations with stakeholders. Barbara Ouellet, Executive Director of the PMPRB, will discuss the highlights of the new Guidelines and their application:
 Reviewing the PMPRB’s Revised Excessive Pricing Guidelines
Determining the implications of the new Guidelines
Gain a clearer understanding of how the new Guidelines will affect you.
 Barbara Ouellet,
Executive Director,
Patented Medicine Prices Review Board
|
| 10:00 am |
Sponsor Exhibit Area – Networking Break
Interact with conference speakers and fellow attendees. |
| 10:30 am |
Panel Discussion
Understanding the Judicial and Practical Implications of PMPRB Developments and What It Means To the Industry
Extend the discussion on the PMPRB developments, and consider how the industry must adapt to the legal and practical implications in order to optimize market access.
What is the impact on brands and the generic community?
How will this affect pharmacy and private payers?
How should plans adapt to keep up with the developments?
 Jeffrey Graham,
Partner,
Borden Ladner Gervais |
 Joan McCormick,
Principal Consultant
Brogan Inc. |
 Doug Worndl,
Partner,
Borden Ladner Gervais |
Claudia Neuber,
Sr. Pricing Manager,
AstraZeneca |
 Moderator: Dimitris Polygenis,
VP, McKesson Specialty,
McKesson Canada |
|
|
| 11:15 pm |
Common Drug Review Policy Update: Changes, Progress and Recommendations
The Common Drug Review (CDR) has undergone changes over the past year and continues to conduct reviews and provide recommendations for formulary listings. As the CDR evolves, industry must stay up to date with the latest changes.
Examine the CDR’s commitments and progress to date
Review recent advisory committee decisions, including new opportunities in reconsiderations
Hear about the future vision for the CDR
Come away with a clear understanding of how the CDR is evolving and what new opportunities are coming.
Karen Lee,
Manager, Health Economics,
Canadian Agency for Drugs and Technologies in Health
|
| 12:00 pm |
Exhibition Area – Networking Luncheon
Join the conference speakers and your peers for a relaxing luncheon. |
| 1:30 pm |
The Impact of Financial Assistance Programs for Patients and the Pharmaceutical
Industry
To address economic struggles experienced by many patients requiring costly therapies, pharmaceutical companies south of the border have publicized their patient assistance programs for unemployed people. How are Canadian manufacturers responding? Are compassionate use and financial assistance programs meeting the needs of Canadians who require high cost medications for chronic or life-threatening diseases? Canadian marketing and reimbursement professionals must stay up to date with financial assistance programs to stay competitive. Gain a better understanding of:
The objective of Financial Assistance programs and are those objectives being met
The structure of Financial Assistance programs with the pros and cons
PMPRB compliance
What benchmarks a pharmaceutical manufacturer should set for a FA program
Stay up-to-date with the latest financial assistance programs in Canada.
 Martin Esterhammer,
President,
Shoppers Drug Mart Specialty Health Network
|
| 2:15 pm |
Optimizing Market Access over a Product’s Lifecycle from the Start: Charting a Strategic Launch Strategy
As the health industry environment evolves, it is important to stay up to date on the latest market developments and to draw out key issues to chart your initiatives and decisionmaking, and maintain your market share for short and longterm success. Create an ironclad launch strategy, covering:
Commercialization and brand planning
Strategic issue management and needs assessments
Patient acquisition and retention strategies
 Kevin West,
Vice President, Operations, Specialty Services,
Innomar Strategies, Inc.
|
| 3:00 pm |
Sponsor Exhibit Area – Networking Break
Continue the debate and discussion with your peers while enjoying a refreshing break. |
| 3:30 pm |
Global Pricing and Reimbursement Trends: Comparing Canadian, European and US Pricing, Reimbursement and HTA Environments
Canadian pricing and reimbursement professionals must stay up to date with what is going on worldwide. Hear about the most current trends.
Role of HTA agencies, assessments and recommendations
Prices and price regulation factors (e.g., internal & external referencing)
Assessing the level of innovation / improvement as part of the P&R process
Cost-effectiveness thresholds vs. budget impact – which is the critical factor for reimbursement?
Risk-sharing and listing agreements for securing reimbursement
The growing role of regional and local decision makers
Outlook and implications of evolving P&R, HTA policies
Stay up-to-date with the latest pricing and reimbursement trends worldwide.
 Neil Palmer,
Vice President, Pricing and Reimbursement,
RTI Health Solutions |
| 4:15 pm |
Case Study: Province of Alberta
Keeping Up with the Evolution of the Alberta Healthcare Delivery System
On July 21, 2009, the Governments of British Columbia and Alberta signed an agreement to consolidate health system supply purchasing, including pharmaceuticals, through a group purchasing organization. The intent is to secure better pricing on pharmaceuticals through the pooling of purchasing volume. Hear more about Alberta’s direction, including:
Take away strategies...
The arrival of the new president and impact on Alberta Health Services
The path to sustainability and expected next steps
The probable impact on pharma
 Laura Fitzgerald,
Principal Consultant,
In Initiative Inc. |
Chad Mitchell,
Procurement & Contracts Manager,
Pharmacy Services,
Alberta Health Services |
|
| 5:00 pm |
Conference Adjourns to Day Two |
| |
Evening Social Activities
Network with industry leaders and stakeholders while enjoying some of the best Toronto has to offer. Start by joining fellow delegates and speakers for complimentary appetizers in the hotel lounge ** |
| |
|
 |
| 8:00 am |
Registration & Sponsor Exhibits Open – Continental Breakfast |
| 8:45 am |
Opening Address From Day Two Chair
Suzanne Lepage,
Private Health Plan Strategist
|
| 9:00 am |
Assessing the Private Payers Environment, Partnerships and Future Challenges
The current private payer environment is in a state of flux. Private Plan Managers are concerned about balancing growing drug plan costs and maintaining the health of their workforce. Understanding the issues and responding to the opportunities and threats can help you prepare and execute effective market access strategies, considering:
Government cost shifting, legislative changes, drug pricing
Patient assistance programs, chronic diseases, debates over the Canada Health Act
Biologic drugs and the looming drug pipeline
Monitor the private payer atmosphere to develop relevant and effective market access strategies.
Suzanne Lepage,
Private Health Plan Strategist |
| 9:45 am |
Panel Discussion
Private Market Agreements in the Canadian Market: Challenges and Opportunities
Canadian private market agreements are a key aspect to optimizing access to therapies. For these agreements to work, there is a need to understand the issues, roles and priorities better of the pharmaceutical and group insurance industries.
 Mike Moriarty,
Principal Consultant,
In Initiative Inc. |
Ron Hoskins
Assistant Vice President,
Group Strategy and Research
Manulife Financial |
 Vic Medland,
President, Group Insurance Services,
Ontario Teachers Insurance Plan |
Lisa Callaghan,
AVP, Market Development,
SunLife Financial |
 Bessie Wang,
Director, Professional Services,
Health Benefits Management Team,
TELUS Health Solutions |
Moderator: Kevin West,
Vice President, Operations,
Specialty Services,
Innomar Strategies, Inc |
|
| 10:30 am |
Sponsor Exhibit Area – Networking Break
Interact with conference speakers and fellow attendees. |
| 11:00 am |
Employers’ Panel
Employers’ Perspective to Health Benefit Plans and How the Pharmaceutical Industry Can Work With Them
Hear the perspective of Canadian employers as they discuss:
The objective of their plans and why they offer benefit plans
How the current market is impacting their benefit plan
What changes have been made recently. What is planned in the short and long term?
What messages they have for the pharmaceutical industry
Find out what employers’ current challenges are and how you can help.
 Will Wilson,
Director, Benefits and
Compensation,
Wal-Mart |
 Laura Mensch,
Senior Vice President,
Health and Benefits Practice,
Aon Consulting |
 Moderator: Tim Clarke,
Benefits Practice Leader,
Hewitt Associates |
 Hugh Paton,
Past Senior Benefits Consultant,
Bell Aliant Regional Communications |
|
| 12:00 pm |
Exhibition Area – Networking Luncheon
Join the conference speakers and your peers for a relaxing luncheon. |
| 1:30 pm |
Case Study: Province of Manitoba
Innovations in Market Access: Challenges and Successes of Utilization Management
Agreements
Manitoba has the highest percentage of publicly funded prescription drug costs in Canada. The province has been working with drug manufacturers with utilization management agreements to help manage rising drug costs. One year in, hear more about:
Value propositions, cost projections and risk sharing mechanisms
The next steps for strengthening the province’s pharmacare program
Opportunities to maximize the potential of products and improve health outcomes
 Olaf Koester,
Director, Drug Management Policy Unit,
Manitoba Health |
| 2:15 pm |
Health Economics: Evaluation of Cost-Effectiveness Thresholds and Signals for Market Access Innovation
In making reimbursement decisions for new healthcare innovations, many governments use explicit methods of cost-effectiveness analysis and cost-utility analyses. It is important that the setting of reimbursement thresholds reflects the economic value of the unit of health benefit.
Optimize threshold levels and R&D investment levels
Recognize the implications of payer reimbursement signals and guidelines
 John Vernon,
Department of Health Policy & Management,
University of North Carolina at Chapel Hill
|
| 3:00 pm |
Sponsor Exhibit Area – Networking Break
Continue the debate and discussion with your peers while enjoying a refreshing break. |
| 3:30 pm |
Thresholds in Canada: Debunking Pharmacoeconomic Myths and Making Sense Of
Outliers
Following upon the previous session, take a closer look into cost-effectiveness thresholds in the Canadian environment. Following a brief overview of thresholds in the UK and Australia, this session will contextualize the threshold and inspect the impact of other non-evidentiary factors in
decision-making in Canada.
Demystifying thresholds in Canadian decision-making
Exploring the influence of sleepers; i.e., social, legal, ethical, equitable, political, etc.
Examining outliers, such as CEDAC decisions that appear to fall outside the acceptable range
 Betsy Miller,
Partner,
Axia Research
|
| 4:15 pm |
Fulfilling the Commitment to Patients: Leveraging Advocacy to Facilitate Market Access
Drug access issues have a profound effect on patients. Even though there are new advances in cancer drug therapies, their cost has risen dramatically. Hear the Canadian Cancer Society’s views on facilitating patients’ access.
Collaborating for patient-focused solutions
Addressing unavailable or inadequate public or private insurance for new expensive treatments
Building momentum for policy changes to improve drug access
Aaron Levo,
Manager of Public Issues,
Canadian Cancer Society
|
| 5:00 pm |
Conference Adjourns |
Post-Conference Workshop: Friday, Nov.6, 2009 | 9:00am ~ 12:00pm
Leveraging Education, Communications and Government Relations Strategies: Advocacy, Communications and Negotiations Planning to Enhance Market Access... see detail >> |
|
